VJOncology is committed to improving our service to you

Share this video  

VJOncology is committed to improving our service to you

ASCO GI 2023 | Recent immunotherapy advances in HCC management

Richard Finn, MD, University of California, Los Angeles, CA, provides an overview of updates in the treatment of hepatocellular carcinoma (HCC). The advent of immunotherapy has greatly enhanced outcomes in patients, especially with doublet regimens such as bevacizumab with atezolizumab, and nivolumab and tislelizumab. However, existing tyrosine kinase inhibitors (TKIs) such as sorafenib, regorafenib, and cabozantinib are still administered in patients, and patients may additionally benefit from ipilimumab. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Gastrointestinal Cancers (GI) Symposium in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter